DREADDs-Based Chemogenetics Induced Slow Transit Constipation via Inhibition of Enteric Neurons

Abstract

Objectives: Designer receptors exclusively activated by designer drugs (DREADDs)-based chemogenetic tools are commonly used to activate or silence targeted neurons by the agonistic ligand deschloroclozapine (DCZ). This study aimed to establish a Gi-DREADD-based murine model of slow transit constipation (STC) and elucidate its pathophysiological mechanisms.

Methods: Adeno-associated virus (AAV) 9-hM4Di was injected into the intestinal wall of mice, and colonic motility was evaluated. The efficiency and immunogenicity of AAV9-hM4Di transduction in the enteric nervous system (ENS) were evaluated. Nitric oxide (NO), acetylcholine (ACh), and substance P (SP) in the colonic tissues and serum samples were analyzed. Calcium (Ca²⁺) imaging was performed to evaluate the responses of AAV9-hM4Di on enteric nerves.

Results: AAV9-hM4Di-treated mice showed gastrointestinal motility dysfunction, including reduced fecal pellets and decreased fecal mass and water content. Electrophysiological recording of muscle contraction in the isolated colonic tissues from the chemogenetic mice showed decreased frequency and amplitude after DCZ treatment. The mice treated with AAV9-hM4Di showed the highest levels of transduction in the myenteric plexuses of the ENS. There were no differences in transduction in neuronal nitric oxide synthase (nNOS) and choline acetyltransferase (ChAT) neurons. Gi-DREADDs significantly downregulated ACh but not NO or SP expression in the distal colon in the chemogenetic mice. Ca²⁺ transient in neurons of ENS in chemogenetic mice was strongly inhibited by DCZ.

Conclusions: It is feasible to apply the DREADDs-based chemogenetic tools to the ENS. Gi-DREADDs can selectively modulate the ENS, inducing STC without excitatory-neural bias, offering targeted neuromodulation for gastrointestinal motility disorders.

Keywords

calcium transient / designer receptors exclusively activated by designer drugs / enteric nervous system / gastrointestinal motility

References

[1] T. Stern and A. M. Davis, “Evaluation and Treatment of Patients With Constipation,” JAMA 315, no. 2 (2016): 192-193.

[2] A. Wald, C. Scarpignato, M. A. Kamm, et al., “The Burden of Constipation on Quality of Life: Results of a Multinational Survey,” Alimentary Pharmacology & Therapeutics 26, no. 2 (2007): 227-236.

[3] J. B. Furness, “The Enteric Nervous System and Neurogastroenterology,” Nature Reviews Gastroenterology & Hepatology 9, no. 5 (2012): 286-294.

[4] A. Ferrara, J. H. Pemberton, R. L. Grotz, and R. B. Hanson, “Prolonged Ambulatory Recording of Anorectal Motility in Patients With Slow-Transit Constipation,” American Journal of Surgery 167, no. 1 (1994): 73-79.

[5] G. Bassotti, F. Chistolini, F. S. Nzepa, and A. Morelli, “Colonic Propulsive Impairment in Intractable Slow-Transit Constipation,” Archives of Surgery 138, no. 12 (2003): 1302-1304.

[6] W. V. B. Fernandes, C. R. Blanco, F. Politti, F. de Cordoba Lanza, P. R. G. Lucareli, and J. C. F. Corrêa, “The Effect of a Six-Week Osteopathic Visceral Manipulation in Patients With Non-Specific Chronic Low Back Pain and Functional Constipation: Study Protocol for a Randomized Controlled Trial,” Trials 19, no. 1 (2018): 151, https://doi.org/10.1186/s13063-018-2532-8.

[7] J. C. Bornstein, M. Costa, and J. R. Grider, “Enteric Motor and Interneuronal Circuits Controlling Motility,” Neurogastroenterology and Motility 16, no. Suppl 1 (2004): 34-38.

[8] C. D. Johnson, A. J. Barlow-Anacker, J. F. Pierre, et al., “Deletion of Choline Acetyltransferase in Enteric Neurons Results in Postnatal Intestinal Dysmotility and Dysbiosis,” FASEB Journal 32, no. 9 (2018): 4744-4752.

[9] B. L. Roth, “DREADDs for Neuroscientists,” Neuron 89, no. 4 (2016): 683-694.

[10] H. Zhu and B. L. Roth, “DREADD: A Chemogenetic GPCR Signaling Platform,” International Journal of Neuropsychopharmacology 18, no. 1 (2014): pyu007, https://doi.org/10.1093/ijnp/pyu007.

[11] E. Vardy, J. E. Robinson, C. Li, et al., “A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior,” Neuron 86, no. 4 (2015): 936-946.

[12] M. E. Carter, M. E. Soden, L. S. Zweifel, and R. D. Palmiter, “Genetic Identification of a Neural Circuit That Suppresses Appetite,” Nature 503, no. 7474 (2013): 111-114.

[13] R. S. Ray, A. E. Corcoran, R. D. Brust, et al., “Impaired Respiratory and Body Temperature Control Upon Acute Serotonergic Neuron Inhibition,” Science 333, no. 6042 (2011): 637-642.

[14] J. L. McClain, D. E. Fried, and B. D. Gulbransen, “Agonist-Evoked Ca²⁺ Signaling in Enteric Glia Drives Neural Programs That Regulate Intestinal Motility in Mice,” Cellular and Molecular Gastroenterology and Hepatology 1, no. 6 (2015): 631-645.

[15] N. Parkar, J. E. Dalziel, N. J. Spencer, P. Janssen, W. C. McNabb, and W. Young, “Slowed Gastrointestinal Transit Is Associated With an Altered Caecal Microbiota in an Aged Rat Model,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1139152, https://doi.org/10.3389/fcimb.2023.1139152.

[16] W. W. Ma, Y. Y. Zhao, Y. Y. Liu, Y. Y. Wang, S. Yu, and L. L. Huang, “Bifidobacterium animalis Subsp. Lactis TG11 Ameliorates Loperamide-Induced Constipation in Mice by Modulating Gut Microbiota,” Frontiers in Microbiology 16 (2025): 1525887, https://doi.org/10.3389/fmicb.2025.1525887.

[17] F. Hayeeawaema, S. Wichienchot, and P. Khuituan, “Amelioration of Gut Dysbiosis and Gastrointestinal Motility by Konjac Oligo-Glucomannan on Loperamide-Induced Constipation in Mice,” Nutrition 73 (2020): 110715, https://doi.org/10.1016/j.nut.2019.110715.

[18] J. Y. Zhang, N. X. Gao, H. Q. Jiang, et al., “Comparative Study on Alleviating Effect of Kiwi Berry (Actinidia arguta) Polysaccharide and Polyphenol Extracts on Constipated Mice,” Food Research International 162, no. Pt A (2022): 112037, https://doi.org/10.1016/j.foodres.2022.112037.

[19] A. Shimotoyodome, S. Meguro, T. Hase, I. Tokimitsu, and T. Sakata, “Decreased Colonic Mucus in Rats With Loperamide-Induced Constipation,” Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology 126, no. 2 (2000): 203-212.

[20] K. D. Foust, E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan, and B. K. Kaspar, “Intravascular AAV9 Preferentially Targets Neonatal Neurons and Adult Astrocytes,” Nature Biotechnology 27, no. 1 (2009): 59-65.

[21] C. Zincarelli, S. Soltys, G. Rengo, and J. E. Rabinowitz, “Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection,” Molecular Therapy 16, no. 6 (2008): 1073-1080.

[22] S. E. Gombash, C. J. Cowley, J. A. Fitzgerald, et al., “Intravenous AAV9 Efficiently Transduces Myenteric Neurons in Neonate and Juvenile Mice,” Frontiers in Molecular Neuroscience 7 (2014): 81, https://doi.org/10.3389/fnmol.2014.00081.

[23] M. J. Benskey, N. C. Kuhn, J. J. Galligan, et al., “Targeted Gene Delivery to the Enteric Nervous System Using AAV: A Comparison Across Serotypes and Capsid Mutants,” Molecular Therapy 23, no. 3 (2015): 488-500.

[24] K. M. Sanders, S. A. Baker, B. T. Drumm, and M. Kurahashi, “Ca²⁺ Signaling Is the Basis for Pacemaker Activity and Neurotransduction in Interstitial Cells of the GI Tract,” Advances in Experimental Medicine and Biology 1383 (2022): 229-241.

[25] Z. D. Qu, M. Thacker, P. Castelucci, M. Bagyánszki, M. L. Epstein, and J. B. Furness, “Immunohistochemical Analysis of Neuron Types in the Mouse Small Intestine,” Cell and Tissue Research 334, no. 2 (2008): 147-161.

[26] K. M. Yeh, O. Johansson, H. Le, et al., “Cystic Fibrosis Transmembrane Conductance Regulator Modulates Enteric Cholinergic Activities and Is Abnormally Expressed in the Enteric Ganglia of Patients With Slow Transit Constipation,” Journal of Gastroenterology 54, no. 11 (2019): 994-1006.

[27] Y. J. Wang, H. Jiang, L. J. Wang, et al., “Luteolin Ameliorates Loperamide-Induced Functional Constipation in Mice,” Brazilian Journal of Medical and Biological Research 56 (2023): e12466, https://doi.org/10.1590/1414-431X2023e12466.

[28] R. Tomita, S. Fujisaki, T. Ikeda, and M. Fukuzawa, “Role of Nitric Oxide in the Colon of Patients With Slow-Transit Constipation,” Diseases of the Colon & Rectum 45, no. 5 (2002): 593-600.

[29] J. D. Huizinga, A. Hussain, and J. H. Chen, “Interstitial Cells of Cajal and Human Colon Motility in Health and Disease,” American Journal of Physiology: Gastrointestinal and Liver Physiology 321, no. 5 (2021): G552-G575.

[30] G. L. McCrea, C. Miaskowski, N. A. Stotts, L. Macera, S. A. Hart, and M. G. Varma, “Review Article: Self-Report Measures to Evaluate Constipation,” Alimentary Pharmacology & Therapeutics 27, no. 8 (2008): 638-648.

[31] B. N. Armbruster, X. Li, M. H. Pausch, S. Herlitze, and B. L. Roth, “Evolving the Lock to Fit the Key to Create a Family of G Protein-Coupled Receptors Potently Activated by an Inert Ligand,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 12 (2007): 5163-5168.

[32] D. J. Urban and B. L. Roth, “DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools With Therapeutic Utility,” Annual Review of Pharmacology and Toxicology 55 (2015): 399-417.

[33] M. J. Berridge, P. Lipp, and M. D. Bootman, “The Versatility and Universality of Calcium Signalling,” Nature Reviews Molecular Cell Biology 1, no. 1 (2000): 11-21.

[34] D. E. Fried and B. D. Gulbransen, “In Situ Ca²⁺ Imaging of the Enteric Nervous System,” Journal of Visualized Experiments no. 95 (2015): 52506, https://doi.org/10.3791/52506.

[35] J. D. Wood and J. J. Galligan, “Function of Opioids in the Enteric Nervous System,” Neurogastroenterology and Motility 16, no. Suppl 2 (2004): 17-28.

[36] W. Chen, H. H. Chung, and J. T. Cheng, “Opiate-Induced Constipation Related to Activation of Small Intestine Opioid μ2-Receptors,” World Journal of Gastroenterology 18, no. 12 (2012): 1391-1396.

[37] M. Y. Zhou, P. Jia, J. P. Chen, et al., “Laxative Effects of Salecan on Normal and Two Models of Experimental Constipated Mice,” BMC Gastroenterology 13 (2013): 52, https://doi.org/10.1186/1471-230X-13-52.

[38] W. Boesmans, M. M. Hao, and P. Vanden Berghe, “Optogenetic and Chemogenetic Techniques for Neurogastroenterology,” Nature Reviews Gastroenterology & Hepatology 15, no. 1 (2018): 21-38.

[39] A. Adamantidis, S. Arber, J. S. Bains, et al., “Optogenetics: 10 Years After ChR2 in Neurons—Views From the Community,” Nature Neuroscience 18, no. 9 (2015): 1202-1212.

[40] A. M. Packer, L. E. Russell, H. W. P. Dalgleish, and M. Häusser, “Simultaneous All-Optical Manipulation and Recording of Neural Circuit Activity With Cellular Resolution In Vivo,” Nature Methods 12, no. 2 (2015): 140-146.

[41] R. Prakash, O. Yizhar, B. Grewe, et al., “Two-Photon Optogenetic Toolbox for Fast Inhibition, Excitation and Bistable Modulation,” Nature Methods 9, no. 12 (2012): 1171-1179.

[42] P. D. Whissell, S. Tohyama, and L. J. Martin, “The Use of DREADDs to Deconstruct Behavior,” Frontiers in Genetics 7 (2016): 70, https://doi.org/10.3389/fgene.2016.00070.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.